文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

以无呼吸机天数为主要结局的临床试验样本量估算:一项系统评价

Sample size estimation in clinical trials using ventilator-free days as the primary outcome: a systematic review.
PubMed 文献 · Crit Care · 2023-08-01
一句话结论26项以无呼吸机天数为主要结局的随机试验中,96%未考虑其偏态分布与死亡的竞争风险,不同统计方法算出的样本量相差1.6至17.4倍。

该系统评价检索PubMed与Embase截至2021年12月、以无呼吸机天数(VFDs)为主要结局的成人随机临床试验,限定为2021年影响因子大于5的同行评议期刊。共纳入26项试验,其中19项(73%)偏倚风险评估为「有些担忧」,24项(92%)为两臂优效性试验,23项(89%)在多中心开展。几乎所有试验(96%)未能考虑VFDs的独特分布及死亡作为竞争风险,VFDs定义(尤其呼吸支持起始时间与类型)和样本量估算方法均存在显著异质性,14项(54%)使用Mann-Whitney-Wilcoxon秩和检验等简单模型,最终样本量计算结果相差1.6至17.4倍。作者认为似乎需要VFDs的标准化定义与方法学(包括核心结局集),以便于试验结果的解读与设计,尤其是需在成本、伦理与统计效能之间权衡的样本量估算。

要点

  • 26项试验中96%未能考虑VFDs的偏态分布及死亡作为竞争风险,这是样本量估算偏差的核心来源。
  • VFDs定义异质性显著,尤其在呼吸支持的起始时间与类型方面各不相同。
  • 样本量估算方法异质,14项(54%)使用Mann-Whitney-Wilcoxon秩和检验等简单模型。
  • 不同方法算出的样本量相差1.6至17.4倍,直接影响试验可行性与统计效能。
  • 19项(73%)试验偏倚风险评估为「有些担忧」;作者认为似乎需要VFDs的标准化定义与方法学(包括核心结局集)。

适用人群与场景

  • 成人随机临床试验,以无呼吸机天数(VFDs)为主要结局,发表于2021年影响因子大于5的同行评议期刊,检索截至2021年12月。

研究设计与关键结果

  • 系统评价共纳入26项临床试验,其中19项(73%)经Cochrane偏倚风险评估工具评定为「有些担忧」。
  • 24项(92%)为两臂优效性试验,23项(89%)在多中心开展。
  • 96%的试验未能考虑VFDs的独特分布以及死亡作为竞争风险。
  • VFDs定义存在显著异质性,尤其在呼吸支持的起始时间和类型方面不一致。
  • 样本量估算方法异质,14项(54%)使用Mann-Whitney-Wilcoxon秩和检验等简单模型。
  • 按不同统计方法计算的样本量相差1.6至17.4倍。

证据类型、等级与局限

  • 证据类型:系统评价,检索PubMed与Embase截至2021年12月,限定2021年影响因子大于5的同行评议期刊,由两名研究者独立提取数据并记录于标准化、经预试验的表单工具,偏倚风险采用Cochrane偏倚风险评估工具。
  • 系统评价注册:PROSPERO ID CRD42021282304,注册日期2021年12月15日。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为似乎需要VFDs的标准化定义与方法学(包括使用核心结局集),以促进临床试验结果的解读与试验构建,尤其是需在成本、伦理与统计效能之间权衡的样本量估算。
  • 现有以VFDs为主要结局的试验中96%未考虑其偏态分布与死亡竞争风险,样本量可因方法不同相差1.6至17.4倍,阅读此类试验时需注意其样本量估算方法与VFDs定义。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Ventilator-free days (VFDs) are a composite endpoint increasingly used as the primary outcome in critical care trials. However, because of the skewed distribution and competitive risk between components, sample size estimation remains challenging. This systematic review was conducted to systematically assess whether the sample size was congruent, as calculated to evaluate VFDs in trials, with VFDs' distribution and the impact of alternative methods on sample size estimation.

METHODS: A systematic literature search was conducted within the PubMed and Embase databases for randomized clinical trials in adults with VFDs as the primary outcome until December 2021. We focused on peer-reviewed journals with 2021 impact factors greater than five. After reviewing definitions of VFDs, we extracted the sample size and methods used for its estimation. The data were collected by two independent investigators and recorded in a standardized, pilot-tested forms tool. Sample sizes were calculated using alternative statistical approaches, and risks of bias were assessed with the Cochrane risk-of-bias tool.

RESULTS: Of the 26 clinical trials included, 19 (73%) raised "some concerns" when assessing risks of bias. Twenty-four (92%) trials were two-arm superiority trials, and 23 (89%) were conducted at multiple sites. Almost all the trials (96%) were unable to consider the unique distribution of VFDs and death as a competitive risk. Moreover, significant heterogeneity was found in the definitions of VFDs, especially regarding varying start time and type of respiratory support. Methods for sample size estimation were also heterogeneous, and simple models, such as the Mann-Whitney-Wilcoxon rank-sum test, were used in 14 (54%) trials. Finally, the sample sizes calculated varied by a factor of 1.6 to 17.4.

CONCLUSIONS: A standardized definition and methodology for VFDs, including the use of a core outcome set, seems to be required. Indeed, this could facilitate the interpretation of findings in clinical trials, as well as their construction, especially the sample size estimation which is a trade-off between cost, ethics, and statistical power. Systematic review registration PROSPERO ID: CRD42021282304. Registered 15 December 2021 ( https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021282304 ).

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Renard Triché L, Futier E, De Carvalho M, et al. Sample size estimation in clinical trials using ventilator-free days as the primary outcome: a systematic review. Crit Care. 2023. PMID: 37528425. doi:10.1186/s13054-023-04562-y

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。